PlumeStars participated at AAPS PharmSci360, the annual Conference of the American Association of Pharmaceutical Scientists, held on October 20-23, 2024 at Salt Palace Convention Center in Salt Lake City, Utah.
This important event featured be keynotes, demonstrations and grand presentations, with insights for both investors and innovation-driven organizations.

The mission of AAPS is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health.
AAPS represents approximately 7,000 individual members and over 10,000 actively participating stakeholders employed in academia, industry, government, and other pharmaceutical science-related research institutes worldwide.

Prof. Paolo Colombo, PlumeStars CEO, attended the conference with Dr. Georgeta Caraua (University of Parma), Dr. Sabrina Banella (University of Verona) and Prof. Gaia Colombo (University of Ferrara).

Dr. Sabrina Banella, in collaboration with PlumeStars, presented a poster titled “Formulation of a Poorly Soluble Antiviral Drug as Microparticle Powder for Nasal Breath Intake Against Respiratory Infections”.

The poster was selected to be presented orally within the Special Poster Collection “Advances in Pulmonary and Nasal Drug Delivery” hosted by Prof. Carsten Ehrhardt (Trinity College of Dublin).

The poster concerns a project aimed to develop a nasal antiviral powder for a timely intervention against respiratory virus infections, such as SARS-CoV-2, influenza, and respiratory syncytial virus.

The goal is to deposit the antiviral drug (ritonavir) not only in the nasal cavity but broadly in the upper airways, concentrating the antiviral drug in infected cells with high precision. To do that, a micronized powder is necessary for nasal breath inhalation delivered using a lung inhalation                                                                                       device adapted to nasal use in an original way.